Advertisement 1

Cannabis researchers find breakthrough treatment for diabetes, high cholesterol

The key is a rare cannabinoid called THCV

Article content

Researchers in the Bay Area have discovered a method to expand production on one of the rarest cannabinoids found in the cannabis plant, THCV. Generally, THCV, or tetrahydrocannabivarin, is only found in trace amounts in most cannabis strains. But the compound, according to scientists, could provide treatments for diabetes, lower cholesterol, and other health benefits.

Advertisement 2
Story continues below
Article content
Recommended from Editorial
  1. Denver wants to erase low-level cannabis convictions
  2. As the root grows and penetrates the soil, it establishes itself
    HOMEGROWN SERIES: Setting the stage for successful cannabis growth
  3. Aphria CEO Vic Neufeld.
    Aphria appoints review committee amidst allegations it is a massive shell game
Article content

“The only thing that THCV does is it’s analgesic and anti-inflammatory, it’s neuroprotective, which means it protects the nervous system,” Dr. Michael Moskowitz, who has been studying THCV, told Mercury News. “It’s anti-nausea and vomiting. It helps with bone health and bone formation, it’s sleep-promoting, it’s anti-epileptic, it’s anti-anxiety. It’s a major anti-psychotic. And it helps with appetite suppression, it’s anti-diabetic and it’s anti-cholesterol.”

“Other than that it didn’t do that much,” Moskowitz added.

Strains with higher THCV levels are believed to have come from Sub-Saharan cannabis plants. Because of a lack of understanding and market desire for marijuana that would produce the biggest “high” in users, growers were breeding strains that would create higher THC levels. This, as it were, came at the detriment of other cannabinoids in the plant.

Advertisement 3
Story continues below
Article content
We apologize, but this video has failed to load.
Try refreshing your browser, or
tap here to see other videos from our team.

Moskowitz, the founder of the Medical Cannabis Research Consortium of Marin, and other Bay Area researchers believe that THCV has the potential to become the new CBD. They plan on competing directly with GW Pharmaceuticals, the parent company behind Epidiolex, the first cannabis-based pharmaceutical approved by the FDA.

According to Mercury News, GW Pharmaceuticals “has also been researching THCV as potential treatment for a variety of diseases and health issues such type II diabetes, schizophrenia, epilepsy, cognitive disorders such as Alzheimer’s, along with several others.”

Whether or not THCV on its own is psychoactive on its own, like THC, remains inconclusive. According to Moskowitz, it has been labeled as both psychoactive and not.

TheFreshToast.com, a U.S. lifestyle site, that contributes lifestyle content and, with their partnership with 600,000 physicians via Skipta, medical marijuana information to The GrowthOp.

Want to keep up to date on what’s happening in the world of cannabis?  Subscribe to the Cannabis Post newsletter for weekly insights into the industry, what insiders will be talking about and content from across the Postmedia Network.

Article content
Comments
You must be logged in to join the discussion or read more comments.
Join the Conversation

Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information.

Latest National Stories
    This Week in Flyers